Stay updated on Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedFooter changes include Revision: v3.3.3 being added and the HHS Vulnerability Disclosure text along with Revision: v3.3.2 being removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedPublications are automatically filled from PubMed and may not be about the study. Revision: v3.3.2 updated from v3.2.0.SummaryDifference0.1%

- Check44 days agoChange DetectedThe government funding status banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check58 days agoChange DetectedThe page’s two screenshots show the same study details with only minor formatting and layout tweaks; there are no additions or removals of core content.SummaryDifference0.3%

- Check87 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check94 days agoChange DetectedUpdate to a citation: the reference moves from Online ahead of print (June 11, 2025) to a finalized in-issue version (June 11) and increments the revision/version from v3.0.2 to v3.1.0.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.